journal
MENU ▼
Read by QxMD icon Read
search

Lancet HIV

journal
https://www.readbyqxmd.com/read/28729158/fixed-dose-combination-dolutegravir-abacavir-and-lamivudine-versus-ritonavir-boosted-atazanavir-plus-tenofovir-disoproxil-fumarate-and-emtricitabine-in-previously-untreated-women-with-hiv-1-infection-aria-week-48-results-from-a-randomised-open-label-non-inferiority
#1
Catherine Orrell, Debbie P Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley, Vicenç Falcó, Choy Y Man, Alicia Aylott, Ann M Buchanan, Brian Wynne, Cindy Vavro, Michael Aboud, Kimberly Y Smith
BACKGROUND: Dolutegravir is a once-daily integrase strand transfer inhibitor with no need for pharmacokinetic boosting that is approved for the treatment of HIV-1 infection. Because women are often under-represented in HIV clinical trials, we addressed the safety and efficacy of dolutegravir in women with HIV-1. METHODS: The ARIA study is a randomised, open-label, multicentre, active-controlled, parallel-group, non-inferiority phase 3b study done in 86 hospital and university infectious disease clinics, local health clinics, and private infectious disease clinics in 12 countries and one US territory, in North America, South America, Europe, Africa, and Asia...
July 17, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28729157/women-in-hiv-trials-improving-adherence-and-outcomes
#2
Susan E Cohn
No abstract text is available yet for this article.
July 17, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28716545/effect-of-ageing-on-neurocognitive-function-by-stage-of-hiv-infection-evidence-from-the-multicenter-aids-cohort-study
#3
Karl Goodkin, Eric N Miller, Christopher Cox, Sandra Reynolds, James T Becker, Eileen Martin, Ola A Selnes, David G Ostrow, Ned C Sacktor
BACKGROUND: The demographics of the HIV epidemic in the USA have shifted towards older age. We aimed to establish the relationship between the processes of ageing and HIV infection in neurocognitive impairment. METHODS: With longitudinal data from the Multicenter AIDS Cohort Study, a long-term prospective cohort study of the natural and treated history of HIV infection among men who have sex with men in the USA, we examined the effect of ageing, HIV infection (by disease stage), and their interaction on five neurocognitive domains: information processing speed, executive function, episodic memory, working memory, and motor function...
July 14, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28716544/does-hiv-prematurely-age-the-brain
#4
Bruce J Brew, Lucette Cysique
No abstract text is available yet for this article.
July 14, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28711527/paediatric-hiv-the-unfinished-business
#5
Martina Penazzato, Frank Lule, Shaffiq Essajee
No abstract text is available yet for this article.
July 12, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28711526/xpert-hiv-1-point-of-care-test-for-neonatal-diagnosis-of-hiv-in-the-birth-testing-programme-of-a-maternity-hospital-a-field-evaluation-study
#6
Karl-Günter Technau, Louise Kuhn, Ashraf Coovadia, Pamela M Murnane, Gayle Sherman
BACKGROUND: Point-of-care testing (POCT) among HIV-exposed infants might improve linkage to care relative to laboratory-based testing (LABT). We evaluated HIV-1 POCT at birth in the context of universal LABT in a maternity hospital and describe our implementation experience. METHODS: We did a field evaluation study between Oct 1, 2014, and April 30, 2016, at the urban Rahima Moosa Mother and Child Hospital (RMMCH), Johannesburg, South Africa. We aimed to sample consecutive neonates at birth with POCT (Cepheid Xpert HIV-1 Qualitative test) and compared results with those of LABT (Roche COBAS TaqMan HIV-1 Qualitative test) with respect to performance in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Cohen's κ coefficient, result return, antiretroviral treatment (ART) initiation, and coverage...
July 12, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28579226/reprising-the-role-of-cd4-cell-count-in-hiv-programmes
#7
Rosanna W Peeling, Nathan Ford
No abstract text is available yet for this article.
May 31, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28579225/effect-of-point-of-care-cd4-cell-count-results-on-linkage-to-care-and-antiretroviral-initiation-during-a-home-based-hiv-testing-campaign-a-non-blinded-cluster-randomised-trial
#8
Mitesh A Desai, Dancun O Okal, Charles E Rose, Richard Ndivo, Boaz Oyaro, Fredrick O Otieno, Tiffany Williams, Robert T Chen, Clement Zeh, Taraz Samandari
BACKGROUND: HIV disease staging with referral laboratory-based CD4 cell count testing is a key barrier to the initiation of antiretroviral treatment (ART). Point-of-care CD4 cell counts can improve linkage to HIV care among people living with HIV, but its effect has not been assessed with a randomised controlled trial in the context of home-based HIV counselling and testing (HBCT). METHODS: We did a two-arm, cluster-randomised, controlled efficacy trial in two districts of western Kenya with ongoing HBCT...
May 31, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28566228/viable-dual-therapy-second-line-antiretroviral-regimen-for-africa
#9
Paula Munderi
No abstract text is available yet for this article.
May 26, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28566227/boosted-protease-inhibitor-monotherapy-versus-boosted-protease-inhibitor-plus-lamivudine-dual-therapy-as-second-line-maintenance-treatment-for-hiv-1-infected-patients-in-sub-saharan-africa-anrs12-286-mobidip-a-multicentre-randomised-parallel-open-label-superiority
#10
Laura Ciaffi, Sinata Koulla-Shiro, Adrien Bruno Sawadogo, Cheik Tidiane Ndour, Sabrina Eymard-Duvernay, Pretty Rosereine Mbouyap, Liliane Ayangma, Jacques Zoungrana, Ndeye Fatou Ngom Gueye, Mohamadou Diallo, Suzanne Izard, Guillaume Bado, Coumba Toure Kane, Avelin Fobang Aghokeng, Martine Peeters, Pierre Marie Girard, Vincent Le Moing, Jacques Reynes, Eric Delaporte
BACKGROUND: Despite satisfactory efficacy of WHO-recommended second-line antiretroviral treatment for patients with HIV in low-income countries, the need for simplified, low-cost, and less-toxic maintenance strategies remains high. We compared boosted protease inhibitor monotherapy with dual therapy with boosted protease inhibitor plus lamivudine in patients on second-line antiretrovial therapy (ART). METHODS: We did a multicentre, randomised, parallel, open-label, superiority, trial in the HIV services of five hospitals in sub-Saharan Africa (Yaoundé, Cameroon; Dakar, Senegal; and Bobo Dioulasso, Burkina Faso)...
May 26, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28546090/safety-and-tolerability-of-long-acting-cabotegravir-injections-in-hiv-uninfected-men-eclair-a-multicentre-double-blind-randomised-placebo-controlled-phase-2a-trial
#11
Martin Markowitz, Ian Frank, Robert M Grant, Kenneth H Mayer, Richard Elion, Deborah Goldstein, Chester Fisher, Magdalena E Sobieszczyk, Joel E Gallant, Hong Van Tieu, Winkler Weinberg, David A Margolis, Krischan J Hudson, Britt S Stancil, Susan L Ford, Parul Patel, Elizabeth Gould, Alex R Rinehart, Kimberly Y Smith, William R Spreen
BACKGROUND: Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in male macaques. We aimed to assess the safety, tolerability, and pharmacokinetics of long-acting cabotegravir injections in healthy men not at high risk of HIV-1 infection. METHODS: We did this multicentre, double-blind, randomised, placebo-controlled, phase 2a trial at ten sites in the USA...
May 22, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28546089/long-acting-cabotegravir-for-prevention-hope-versus-reality
#12
Sheena McCormack, Marta Boffito
No abstract text is available yet for this article.
May 22, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28515015/collateral-damage-and-the-criminalisation-of-drug-use
#13
Lisa Maher, Thomas Crewe Dixon
No abstract text is available yet for this article.
May 12, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28515014/hiv-and-the-criminalisation-of-drug-use-among-people-who-inject-drugs-a-systematic-review
#14
Kora DeBeck, Tessa Cheng, Julio S Montaner, Chris Beyrer, Richard Elliott, Susan Sherman, Evan Wood, Stefan Baral
BACKGROUND: Mounting evidence suggests that laws and policies prohibiting illegal drug use could have a central role in shaping health outcomes among people who inject drugs (PWID). To date, no systematic review has characterised the influence of laws and legal frameworks prohibiting drug use on HIV prevention and treatment. METHODS: Consistent with PRISMA guidelines, we did a systematic review of peer-reviewed scientific evidence describing the association between criminalisation of drug use and HIV prevention and treatment-related outcomes among PWID...
May 12, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28501496/improved-life-expectancy-of-people-living-with-hiv-who-is-left-behind
#15
Ingrid T Katz, Brendan Maughan-Brown
No abstract text is available yet for this article.
May 10, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28501495/survival-of-hiv-positive-patients-starting-antiretroviral-therapy-between-1996-and-2013-a-collaborative-analysis-of-cohort-studies
#16
(no author information available yet)
BACKGROUND: Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013. METHODS: We analysed data from 18 European and North American HIV-1 cohorts...
May 10, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28495563/resistance-matters-in-earnest
#17
Gary Maartens, Graeme Meintjes
No abstract text is available yet for this article.
May 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28495562/nucleoside-reverse-transcriptase-inhibitor-cross-resistance-and-outcomes-from-second-line-antiretroviral-therapy-in-the-public-health-approach-an-observational-analysis-within-the-randomised-open-label-earnest-trial
#18
Nicholas I Paton, Cissy Kityo, Jennifer Thompson, Immaculate Nankya, Leonard Bagenda, Anne Hoppe, James Hakim, Andrew Kambugu, Joep J van Oosterhout, Mary Kiconco, Silvia Bertagnolio, Philippa J Easterbrook, Peter Mugyenyi, A Sarah Walker
BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the association between the activity, predicted by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients infected with HIV. METHODS: We did an observational analysis of additional data from a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa...
May 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28668184/correction-to-lancet-hiv-2017-4-e240
#19
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Lancet HIV
https://www.readbyqxmd.com/read/28668183/social-change-and-hiv-in-iran-reaching-hidden-populations
#20
Masoud Mozafari, Kenneth H Mayer
No abstract text is available yet for this article.
July 2017: Lancet HIV
journal
journal
49635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"